Skin Toxicity Seen In Other DPP-4 Inhibitors Missing In Januvia – FDA Review

FDA requested that Merck conduct an additional study in primates during its review of Januvia (sitagliptin) due to concerns of necrotoxicity that were based on similar findings seen with other DPP-4 inhibitors

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet